San Francisco, CA, 2 - 5 December 2019
Schedule
Create your personal agenda –check the favourite icon
Dec 212:59
Conference pass
Workshop B: Advances in adjuvant technology for vaccines
WORKSHOP B
Advances in adjuvant technology for vaccines:Vaccine adjuvants have been used successfully for decades to enhance the ability to provoke an immune response of weak antigens and improve the overall potency of vaccines. Join this workshop to explore the latest advances in novel adjuvant technology for vaccines, the value of current adjuvants and how to improve them.
Dec 213:00
Conference pass
Workshop A: Uses and clinical application of immune profiling assays for cancer
WORKSHOP A
The use of novel assays and computational methods to analyse the immune system is a very fast-moving field and it is challenging to keep up with the pace of change. Join our Advances in Immune Profiling Assays workshop on 2nd December for an in depth look at the uses and clinical application of new methods to characterise and profile the human immune system for the accelerated development of new therapies.Topics:·Measuring base-line immune function ·Assessing predictive biomarkers for PD1 / PDL1 immunotherapies·How to assess the efficacy and longevity of cellular therapies·Characterising the tumor microenvironment·Discovery of genomic predictors and genomic alterations that promote or suppress immune response·Discovery and development of novel biomarkers
Dec 213:00
Conference pass
Adjuvant technology and its impact on vaccine development
WORKSHOP B
Dec 213:30
Conference pass
Use of receptor agonists in improving existing adjuvants or designing new novel adjuvants for different animal species
WORKSHOP B
Dec 214:00
Conference pass
Precision adjuvants; tailoring immune activation for next generation vaccines
WORKSHOP B
Dec 214:30
Conference pass
The cGAS-STING Pathway as a Target for Enhancing Vaccine Efficacy, Antiviral Therapeutics, and Cancer Immunotherapy
WORKSHOP B
Victor Defilippis, Associate Professor, Oregon Health and Science
Dec 215:30
Conference pass
Evaluation of Human Vaccines prior Vaccination: Of Hope and Hype
WORKSHOP B
Create your personal agenda –check the favourite icon
Dec 308:30
Conference pass
Immunotherapy 2020 and beyond – what are the next frontiers?
Keynotes
- In the last 10 years ground breaking advances and progress have been made in the treatment of cancer with immunotherapy-based approaches.
- We have seen approvals of cancer vaccines, multiple single agent and combination checkpoint inhibitor agents in a broad range of tumor types, tissue-agnostic immunotherapy and cellular and gene therapies.
- These agents are improving survival and providing cures in some cancer patients.
- Several new immunotherapy advancements, opportunities and challenges are on the horizon.
Dec 308:50
Conference pass
Advances in integrative analysis of single cell sequencing and multiple omics data for a better understanding of response to immunotherapy and vaccination
Keynotes
- Advances in the development of novel computational methods to understand response to therapy in infectious diseases and cancer
- Challenges associated with large data volumes and numerous measured variables on statistical power with small sample sizes
- Use of correlation and mechanistic connections to overcome challenges with high dimensional data
- Important components of software platforms for data management and analysis and how they can be improved
- Challenges of missing or incomplete data in multi-omic datasets
Dec 309:45
Conference pass
The use of vaccines and antibodies in biodefense strategies to combat emerging threats
Keynotes
Dec 310:30
Conference pass
Morning Networking Break
Keynotes
Meet the Investor Speed Networking: Meet, exchange interests and swap business cards with investors in the biotechnology sector. A great opportunity to maximize your time at the event and meet up to 10 investors in 15mins. Investors include:
Kristen Wong, Associate, Altitude Life Science Ventures
David Maki, General Partner, Altitude Life Science Ventures
Michael Tippie, General Manager, Alignment Ventures
Dec 311:30
Conference pass
Chair’s Opening Remarks
Immune Profiling
Dec 311:30
Conference pass
Chair’s Opening Remarks:
Cancer Immunotherapy
Dec 311:30
Conference pass
Chair’s Opening Remarks
New Technology
Dec 311:40
Conference pass
Development and validation of biomarkers for diagnosis and prediction of response resistance to treatment
Immune Profiling
Dec 311:40
Conference pass
Should each patient’s immune system inform their immunotherapy?
Cancer Immunotherapy
- ATLAS™, an autologous immune assay that identifies specific immunogenic neoantigens, is more effective at identifying immunogenic CD4 AND CD8 targets than algorithms
- High variability between patients shows that each individual’s immune system evolves differently throughout their lives
- Immunosuppressive peptides, identified only through ATLAS, can undercut immunity and compromise immune function
Dec 311:40
Conference pass
Innovating vaccine development in space
New Technology
Dec 311:40
Conference pass
How are pharmaceutical companies contributing to the fight against antibiotic resistance with the use of vaccines
Vaccine Development
Dec 312:10
Conference pass
Intralesional IL12 enhances anti-PD-1 immune response in treatment-refractory solid tumors
Immune Profiling
- Intro
- Plasmid DNA electroporation platform
- KEYNOTE-695 Clinical trial highlights
- Biomarker data
- Conclusion
Dec 312:10
Conference pass
An integrated machine-learning approach to improve the prediction of clinically relevant neoantigens
Cancer Immunotherapy
- We will outline a high performing machine learning approach that predicts naturally presented antigens to the tumor cell surface
- The predictor, known as the Immuneoprofiler, is integrated with several immune parameters in a deep learning layer
- We illustrate the application of the Immuneoprofiler to significantly improve the identification of neoantigen targets for personalised cancer immunotherapy
Dec 312:10
Conference pass
RosettaAntibodyDesign - a platform for computational antibody design
New Technology
Dec 312:40
Conference pass
Determinants of clinical response to CAR-T therapy
Immune Profiling
Dec 312:40
Conference pass
Artificial Intelligence to the rescue: towards personalized, neoantigen-targeted immunotherapeutics
Cancer Immunotherapy
Dec 312:40
Conference pass
Introducing a new bioparticle platform; design, polyvalence, production and immunomodulatory potential
New Technology
Dec 312:40
Conference pass
Update on the development and use of a single-dose live oral cholera vaccine
Vaccine Development
Dec 312:55
Conference pass
Development of EcoCRM®, a new GMP CRM197 carrier protein
New Technology
Dec 313:10
Conference pass
Networking lunch and poster session
Keynotes
Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area. Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies
Dec 314:10
Conference pass
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types
Cancer Immunotherapy
- Development of new paradigm shifting cancer immune-therapies
- translational strategies from basic preclinical studies to clinical trials
- detailed pipeline/ portfolio of validated B-cell peptide vaccines
- Development of combinatorial immunotherapeutic strategies
Dec 314:10
Conference pass
Targeting highly conserved influenza virus epitopes with self-assembled peptides
New Technology
- A new vaccine platform is being developed that targets B cell epitopes derived from host and microbial proteins.
- Peptides synthesized with epitopes from the viral M2e, neuraminidase, and hemagglutinin stem proteins induce protective antibody responses in challenged mice.
- These results suggest a path forward for the development of a universal influenza vaccine.
Dr Chris Clegg, President, Founder and Chief Scientific Officer, TRIA Bioscience
Dec 314:10
Conference pass
Development of a bioconjugate vaccine against E. coli
Vaccine Development
Dec 314:40
Conference pass
Decoding cell-free biomarker patterns to optimize the next generation of precision immunotherapies
Immune Profiling
Dec 314:40
Conference pass
Pfizer’s vaccine immunotherapy combination regimen for cancer
Cancer Immunotherapy
Dec 314:40
Conference pass
Vaccine development in Chikungunya, a severe disease with debilitating long-term effects and global outbreak potential
New Technology
Dec 314:40
Conference pass
Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse
Vaccine Development
Dec 315:10
Conference pass
Overview of Immune Epitope Database
Immune Profiling
Overview of Immune Epitope Database
- What does the IEDB do?
- How to access data
- Predictive tools
- How does this integrate into other databases?
Dec 315:10
Conference pass
Mesenchymal stem cells as a novel approach for optimization of oncolytic virus delivery
Cancer Immunotherapy
Dec 315:10
Conference pass
Peptide-based checkpoint receptor inhibitors as adjuvants and therapeutics in infectious diseases
New Technology
Dec 315:10
Conference pass
Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus
Vaccine Development
Dec 315:40
Conference pass
Susceptible or Immune? A CMV T cell assay accurately predicts patient status
Immune Profiling
- Cellular immunity is key to controlling many viral infections, particularly in high risk populations.
- A flow cytometry based, intracellular cytokine detection method has been developed and validated to measure CD4 and CD8 T cell responses to CMV antigen.
- Clinical studies have demonstrated strong sensitivity, specificity, positive predictive values and negative predictive values for CMV viremia and disease.
Dec 315:40
Conference pass
Increasing effectiveness of oncolytic virus therapy
Cancer Immunotherapy
Dec 315:40
Conference pass
Supercharging immunotherapy with novel vector technology harnessing the exceptional immunogenicity of arenaviruses
New Technology
Dec 315:40
Conference pass
Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis
Vaccine Development
Dec 315:55
Conference pass
A novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines
New Technology
Dec 316:40
Conference pass
Induction of innate immunity against bacterial infection
Immune Profiling
Dec 316:40
Conference pass
Immulytic; achieving personalized systemic neoantigen vaccination directly in the patient
Cancer Immunotherapy
Dec 316:40
Conference pass
A novel hybrid virus-like-particle technology to accelerate the conversion of antigenic epitopes into efficient immunogens deliverable as vaccines
New Technology
Dec 316:40
Conference pass
Oral Norovirus Tablet Vaccine
Vaccine Development
Dec 317:10
Conference pass
Developing and utilizing positional scanning combinatorial libraries for T-lymphocyte antigen discovery
Immune Profiling
- General concepts and illustration of positional scanning combinatorial libraries composed of trillions of peptides
- T cell driven antigen identification approach integrates the screening results of positional scanning libraries and protein databases
- Examples of the elucidation of the peptide and antigen specificity of T cells with unknown specificity
Dec 317:10
Conference pass
Advantages of HSV-based oncolytic virus therapies for the treatment of solid tumors
Cancer Immunotherapy
Andreas Niethammer, Senior Vice President, Head of Clin Development, Immunotherapy Solid Tumors, Sorrento Therapeutics Inc
Dec 317:10
Conference pass
Unique immunotherapy approach, based on an oncolytic virus non-covalently combined with tumor-specific peptides, for a highly immunogenic and rapidly adaptable tumor vaccination platform.
New Technology
Dec 317:10
Conference pass
Vaccinating against the poverty-related neglected diseases
Vaccine Development
Dec 317:40
Conference pass
Human in vitro modeling to inform precision vaccines for vulnerable populations
Immune Profiling
Dec 317:40
Conference pass
Armed and dangerous against cancer: TGF-beta trap and personalized oncolytic adenoviruses
Cancer Immunotherapy
- Positive clinical data from first two patients treated with personalized i.e., neoantigen enhanced oncolytic adenoviruses
- Data from TGF-beta trap virus, which is only months away from a Phase 1 trial, that shows abscopal anticancer activity and evidence of cold-to-hot tumor transformation
- Biodistribution data from intravenous and intratumoral administration of the TGF-beta trap virus, which demonstrates persistent non-negligible serum levels of the TGF-beta trap
Dec 317:40
Conference pass
Developing multi-target single-vector vaccines and delivery devices for Venezuelan Equine Encephalitis Virus (VEEV)
New Technology
Dec 317:40
Conference pass
Understanding the immunology of syphilis using modern technology to develop a vaccine against this resurgent pathogen
Vaccine Development
Create your personal agenda –check the favourite icon
Dec 408:30
Conference pass
Chairs Opening Remarks
Clinical Development
Dec 408:30
Conference pass
Chairs Opening Remarks:
Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 408:40
Conference pass
Mucosal delivery of universal flu vaccine antigens in animal models
Vaccine Development
Dec 408:40
Conference pass
Pre-clinical toxicology considerations for vaccine development
Clinical Development
Dec 408:40
Conference pass
Recurrent Stage 4 Cancer: A patient’s journey and hope for the future
Engaging T-Cells, Cancer Antibodies, and Combinations
Chester Kitchen, Cancer Patient Advocate
Dec 408:40
Conference pass
Opportunities and challenges for integrating delivery technologies into cancer immunotherapy
Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 409:10
Conference pass
Developing a single vaccine to protect against all influenza strains using ground-breaking mathematical models and research
Vaccine Development
Dec 409:10
Conference pass
Novel correlates of protection against pandemic influenza
Clinical Development
Dec 409:10
Conference pass
Combinations and checkpoint inhibitors; what’s working?
Engaging T-Cells, Cancer Antibodies, and Combinations
- Landscape of combination therapies – why aren’t they working?
- PD1 resistance – what are the major mechanisms we need to focus on?
Dec 409:10
Conference pass
Development of novel antibody-directed nanotherapeutics (ADN) for infectious diseases and cancer
Immunotherapy Bioprocessing, Manufacture & Delivery
Daryl Drummond, Biotechnology Consultant
Dec 409:40
Conference pass
Broader protective influenza vaccine
Vaccine Development
Dec 409:40
Conference pass
The Potential Impact of a Norovirus Vaccine in the U.S.
Clinical Development
Dec 409:40
Conference pass
Targeting soluble TNF to overcome trastuzumab resistance in HER2+ breast cancer
Engaging T-Cells, Cancer Antibodies, and Combinations
- MUC4 expression predicts trastuzumab resistance in HER2+ breast cancerMUC4 expression is driven by soluble TNFNeutralization of sTNF with INB03 prevents trastuzumab resistance in women with MUC4+/HER2+ breast cancer
Dec 409:40
Conference pass
Engineering bispecific IgM antibodies as cancer therapeutics
Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 410:10
Conference pass
Protection against Respiratory Syncytial Virus (RSV) by maternal immunization
Vaccine Development
Dec 410:10
Conference pass
Executing animal rule studies in high containment
Clinical Development
Dec 410:10
Conference pass
Versamune; a novel T-cell activating immunotherapy platform
Engaging T-Cells, Cancer Antibodies, and Combinations
Versamuneâ (R-DOTAP nanoparticles) works by facilitating several critical immunological mechanisms:
- Superior in vivo priming of tumor antigens through dendritic cell uptake and destabilization of the endosomal membrane, enabling associated antigens to effectively access the class-I and class-II MHC pathways to prime tumor (HPV)-specific CD8+ and CD4+ T cells.
- Potent immune activation as a result of dendritic cell maturation, induction of Type 1 interferon and critical chemokines within lymph nodes that promote T cell migration, activation and proliferation within the lymphatics.
- Significant increase in CD8+ tumor infiltration with lowering of the Treg to CD8+ T cells ratio within the tumor microenvironment, resulting in “de-camouflaging” of tumors.
- Induction of robust memory T cell responses resulting in protection from tumor re-challenge following treatment with R-DOTAP and HPV-E7 peptides in preclinical animal studies.
- Systemic bioavailability of <6% associated with a lack of significant cytokine release and non-specific systemic immune activation, resulting in a highly favorable safety profile for use in combination with other I-O agents and approaches.
Dec 410:10
Conference pass
Design & manufacture of next generation biotherapeutics with a scalable biochemical protein synthesis platform
Immunotherapy Bioprocessing, Manufacture & Delivery
- Introduction to Sutro’s proprietary Cell Free Protein Expression Technology.
- How the rapid cycle time of the CF reaction allows for high throughput screening of designed structural variants, including incorporation of non-natural amino acids, to enable development of optimal proteins for both function and manufacturability.
- Demonstration of successful scale up from microliters at bench scale to 1000 liters in a GMP manufacturing environment.
Dec 410:25
Conference pass
Using serology to support vaccine development
Clinical Development
Dec 411:30
Conference pass
Interactive Roundtables - Click to View
Keynotes
Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development (Roundtables run twice each for 45mins, select two options)
Advances in the intratumoral administration of cancer agents
Best practices for outsourcing manufacture of biologics through CMOs
Early engagement of sites: Advantages for sponsors and CROs
Flavivirus vaccine – induced immune responses using mouse models
Generation of antibodies to novel targets
Influenza vaccination and the diversity paradox
Managing process improvements for vaccines
Managing toxicity in combination immunotherapy
Pamela Munster, Professor, University of California San Francisco
Meet the investor: your questions answered
Strategies to improve patient stratification by interrogating the tumor microenvironment
The road map to NIH’s grant application process. How to find out more about the current programs available
Dr Susan Old, Deputy Director Of The Division Of Extramural Activities, NIAID
Dec 413:10
Conference pass
Networking Lunch and Poster session
Keynotes
Innovation & Start up Zone – hear emerging biotechs present their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area.
Dec 414:30
Conference pass
A novel live attenuated RSV vaccine
Vaccine Development
Dec 414:30
Conference pass
Location, Location, Location: How tissue residency influences T cell function and protective capacity
Clinical Development
Dec 414:30
Conference pass
CD40 agonists to enhance antigen presentation, resulting in improved quality and magnitude of T-cell responses
Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 415:00
Conference pass
Next generation Pneumococcal bioconjugate vaccine, multivalent Klebsiella pneumoniae and Group B Streptococcus bioconjugate vaccine
Clinical Development
Dec 415:00
Conference pass
A novel WT1-targeting multivalent heteroclitic epitope immunotherapeutic: clinical update
Engaging T-Cells, Cancer Antibodies, and Combinations
· WT1 antigen biology· Overview of galinpepimut-S technology· Updates in galinpepimut-S clinical data· Upcoming phase 3 trial
Dec 415:30
Conference pass
Designing Immuno-Oncology trials to maximizing clinical outcomes and chances of success
Clinical Development
Dec 415:30
Conference pass
Leveraging bispecific molecules for the combination immunotherapy of cancer
Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 416:30
Conference pass
A natural killer T (NKT) cell adjuvanting vaccine platform induces liver-resident memory CD8+ T cells that protect against malaria
Vaccine Development
Dec 416:30
Conference pass
Developing allogeneic cancer immunotherapy with iPSC technology
Immunotherapy Bioprocessing, Manufacture & Delivery
- Fate is pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from ourproprietary iPSC platformto derive cell therapy product candidates that can be delivered off-the-shelf for the treatment of a large number of patients.
- Ourcell therapy product candidate pipelineis comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates derived from master iPSC lines
- Discuss challenges in cell culture scale up for allogeneic cell therapies with iPSC technology
Dec 417:00
Conference pass
Trial Designs for Vaccine Therapies and Personalized Medicine in Oncology
Clinical Development
Mary Redman, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Dec 417:00
Conference pass
Developing Antibody-Drug-Conjugates to unique embryonic cancer stem cell targets
Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 417:00
Conference pass
Improving autologous CAR-T access and affordability
Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 417:30
Conference pass
Development of single dose vaccines for emerging and re-emerging infectious diseases, preclinical data for Ebola, Marburg, Lassa Fever and Zika as examples
Vaccine Development
Dec 417:30
Conference pass
Clinical development of next generation Antibody Drug Conjugates
Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 417:30
Conference pass
Designing cutting edge vaccine and biotechnology manufacturing platforms
Immunotherapy Bioprocessing, Manufacture & Delivery
*topic title TBC
Charles Heffernan, Member, BioPhorum Operations Group; Director, C.R.B.
Create your personal agenda –check the favourite icon
Dec 509:10
Conference pass
Clinical Trials in an International Setting
Clincal Development
Jo Anne Welsch, Scientific Director, Path
Dec 509:10
Conference pass
Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors
Engineered Cancer Therapies
Dec 509:10
Conference pass
Development and licensure of an Ebola vaccine
Vaccine Delivery, Bioprocessing & Manufacture
Risat Jannat, Director, Global Vaccines & Biologics Commercialization,, Merck
Dec 509:10
Conference pass
Passive immunity strategies in infectious diseases
Infectious Disease Antibodies
Dec 509:40
Conference pass
Advances in development of conjugate and multi-component vaccines
Vaccine Delivery, Bioprocessing & Manufacture
- The past three decades have witnessed the development and commercial licensure of several multivalent conjugate vaccines against several medically important bacterial pathogens, includingHaemophilus influenzaetype b,Streptococcus pneumoniae,Neisseria meningitidis, andSalmonella typhi. The development of these multivalent conjugate vaccines and new multicomponent candidates, currently in clinical trials, comprising additional protein antigens involves a complex strategy due to the varying structural, process and stability requirements posed by several antigens.The continued addition of more and more antigens to these multicomponent vaccines brings new challenges such as immune interference impacting vaccine efficacy.The presentation will address specific development strategies to address some of the challenges associated with advances in conjugate antigens, comprising these multivalent and multicomponent vaccines.
Dec 509:55
Conference pass
Experimental human challenge models used in respiratory track diseases and malaria
Clincal Development
Dec 510:10
Conference pass
A unique platform for research scale to mid-scale, host-independent biological manufacturing
Vaccine Delivery, Bioprocessing & Manufacture
Dec 510:10
Conference pass
Anti-Ebola mAbs currently being used in the Ebola outbreak in DRC
Infectious Disease Antibodies
Dec 510:25
Conference pass
Site’s perspective on frequent issues around vaccine trials
Clincal Development
(Title TBC)
Dec 511:10
Conference pass
Targeting natural neoantigens through adoptive cellular therapies
Engineered Cancer Therapies
Dec 511:10
Conference pass
Monoclonal antibody development against infectious diseases in pediatric populations
Infectious Disease Antibodies
Dec 511:40
Conference pass
Drug development challenges within immune-oncology and analytical approaches to address them
Clincal Development
Dec 511:40
Conference pass
Identification of novel T-cell receptor targets and specificity profiling of TCRs tested in the clinic to develop safe & effective TCR therapies
Engineered Cancer Therapies
Dec 511:40
Conference pass
Challenges in vaccine manufacture in LMICs
Vaccine Delivery, Bioprocessing & Manufacture
Dec 511:40
Conference pass
Antibody-based therapy to combat Staphylococcus aureus infections
Infectious Disease Antibodies
Dec 512:10
Conference pass
Immuno-STAT – A novel platform for the selective modulation of antigen-specific T-cells
Engineered Cancer Therapies
Dec 512:10
Conference pass
VsmAp™, Adjuvants, and VaxiPatch™ a new complete Influenza Vaccine solution that promises to improve vaccine protection, eliminate needle phobia, the cold chain and sharps waste
Vaccine Delivery, Bioprocessing & Manufacture
- Verndari offers a completely modern influenza vaccine
- VsmApTM, (vaccine synthetic membrane antigen presentation)
- Advanced Adjuvants
- VaxiPatchTM Delivery – painless and room temperature stability
- Verndari Vaccination Kit capable of mail distribution
Dec 512:10
Conference pass
Development of antibiotic drug conjugates
Infectious Disease Antibodies
Dec 512:40
Conference pass
Gamma delta T-cells: A universal, off-the-shelf immune cell therapy to treat cancer and other diseases
Engineered Cancer Therapies
Dec 512:40
Conference pass
Development of a versatile, single-injection vaccine formulation platform that can enhance immune response
Vaccine Delivery, Bioprocessing & Manufacture
Dec 514:20
Conference pass
Microbiome and epigenetic imprinting of immune responses to vaccination in humans
Keynotes
Dec 514:50
Conference pass
What will be the impact of moving towards earlier lines of therapy in cancer?
Keynotes
- How will this change how we think about resistance?
- What happens when we reach maximal amount of t-cell responses?
- If immune capability decreases with subsequent lines of therapy is it a good idea to delay? Will investigational therapies preclude a patient from getting chemo?
- Modifying the immune system to respond to immunotherapy
- How does immunotherapy interact with radiation?
- How will this affect drug candidate pipelines?
last published: 16/Oct/19 13:05 GMT
Contact us
To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156
oliver.breed@terrapinn.com
To speak:
Lauren Sheppard
+44 (0)207 092 1211
lauren.sheppard@terrapinn.com
Organiser
